Which has preferable valuation and earnings, BCAX or CNTA?

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A Centessa Pharmaceuticals N/A N/A -$197.53M -$1.79 N/A

Is BCAX or CNTA more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Centessa Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -35.89% -33.78% Centessa Pharmaceuticals N/A -60.37% -44.17%

Does the media favor BCAX or CNTA?

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 2 mentions for Bicara Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.96 beat Bicara Therapeutics' score of 0.94 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Centessa Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, COGT or BCAX?

Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cogent Biosciences N/A N/A -$328.94M -$2.17 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is COGT or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Cogent Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cogent Biosciences N/A -104.27% -54.64% Bicara Therapeutics N/A -35.89% -33.78%

Does the media favor COGT or BCAX?

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. Cogent Biosciences' average media sentiment score of 0.94 equaled Bicara Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cogent Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BLTE or BCAX?

Belite Bio is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.53 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is BLTE or BCAX more profitable?

Belite Bio's return on equity of -13.14% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -13.14% -12.88% Bicara Therapeutics N/A -35.89% -33.78%

Which has higher earnings and valuation, SRRK or BCAX?

Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.59 N/A Bicara Therapeutics N/A N/A -$137.95M -$2.78 N/A

Is SRRK or BCAX more profitable?

Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -163.52% -96.67% Bicara Therapeutics N/A -35.89% -33.78%

Does the media refer more to SRRK or BCAX?

In the previous week, Scholar Rock had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 4 mentions for Scholar Rock and 2 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.94 beat Scholar Rock's score of 0.81 indicating that Bicara Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BCAX or CGON more profitable?

CG Oncology's return on equity of -23.33% beat Bicara Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Bicara Therapeutics N/A -35.89% -33.78% CG Oncology N/A -23.33% -22.24%

Does the media favor BCAX or CGON?

In the previous week, CG Oncology had 10 more articles in the media than Bicara Therapeutics. MarketBeat recorded 12 mentions for CG Oncology and 2 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.94 beat CG Oncology's score of 0.63 indicating that Bicara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bicara Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bicara Therapeutics (BCAX) Competitors

$29.69 +0.35 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$29.67 -0.02 (-0.07%)

As of 05:53 PM Eastern

Compare

BCAX vs. CNTA, COGT, BLTE, SRRK, and CGON

Should you buy Bicara Therapeutics stock or one of its competitors? MarketBeat compares Bicara Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bicara Therapeutics include Centessa Pharmaceuticals (CNTA), Cogent Biosciences (COGT), Belite Bio (BLTE), Scholar Rock (SRRK), and CG Oncology (CGON). These companies are all part of the "pharmaceutical products" industry.

How does Bicara Therapeutics compare to Centessa Pharmaceuticals?

Bicara Therapeutics (NASDAQ:BCAX) and Centessa Pharmaceuticals (NASDAQ:CNTA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, risk, valuation, institutional ownership, media sentiment, profitability and dividends.

Bicara Therapeutics' return on equity of -35.89% beat Centessa Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
Centessa Pharmaceuticals	N/A	-60.37%	-44.17%

Centessa Pharmaceuticals is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
Centessa Pharmaceuticals	N/A	N/A	-$197.53M	-$1.79	N/A

Bicara Therapeutics has a beta of -0.54, meaning that its share price is 154% less volatile than the broader market. Comparatively, Centessa Pharmaceuticals has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Bicara Therapeutics currently has a consensus price target of $30.27, suggesting a potential upside of 1.96%. Centessa Pharmaceuticals has a consensus price target of $41.33, suggesting a potential upside of 2.06%. Given Centessa Pharmaceuticals' higher possible upside, analysts clearly believe Centessa Pharmaceuticals is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
Centessa Pharmaceuticals	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

In the previous week, Centessa Pharmaceuticals had 1 more articles in the media than Bicara Therapeutics. MarketBeat recorded 3 mentions for Centessa Pharmaceuticals and 2 mentions for Bicara Therapeutics. Centessa Pharmaceuticals' average media sentiment score of 0.96 beat Bicara Therapeutics' score of 0.94 indicating that Centessa Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Centessa Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

82.0% of Centessa Pharmaceuticals shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by company insiders. Comparatively, 4.1% of Centessa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Bicara Therapeutics beats Centessa Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Cogent Biosciences?

Cogent Biosciences (NASDAQ:COGT) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

Bicara Therapeutics' return on equity of -35.89% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cogent Biosciences	N/A	-104.27%	-54.64%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Cogent Biosciences currently has a consensus target price of $43.73, suggesting a potential upside of 12.99%. Bicara Therapeutics has a consensus target price of $30.27, suggesting a potential upside of 1.96%. Given Cogent Biosciences' stronger consensus rating and higher probable upside, research analysts clearly believe Cogent Biosciences is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Cogent Biosciences and Cogent Biosciences both had 2 articles in the media. Cogent Biosciences' average media sentiment score of 0.94 equaled Bicara Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cogent Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cogent Biosciences has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.54, suggesting that its share price is 154% less volatile than the broader market.

Cogent Biosciences is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Summary

Cogent Biosciences and Bicara Therapeutics tied by winning 5 of the 10 factors compared between the two stocks.

How does Bicara Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, media sentiment, profitability and risk.

Belite Bio currently has a consensus target price of $203.00, indicating a potential upside of 31.83%. Bicara Therapeutics has a consensus target price of $30.27, indicating a potential upside of 1.96%. Given Belite Bio's higher possible upside, equities research analysts plainly believe Belite Bio is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

In the previous week, Bicara Therapeutics had 1 more articles in the media than Belite Bio. MarketBeat recorded 2 mentions for Bicara Therapeutics and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.86 beat Bicara Therapeutics' score of 0.94 indicating that Belite Bio is being referred to more favorably in the media.

Company	Overall Sentiment
Belite Bio	Very Positive
Bicara Therapeutics	Positive

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Belite Bio has a beta of -1.24, meaning that its stock price is 224% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.54, meaning that its stock price is 154% less volatile than the broader market.

Belite Bio's return on equity of -13.14% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-13.14%	-12.88%
Bicara Therapeutics	N/A	-35.89%	-33.78%

Belite Bio is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.53	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Summary

Belite Bio and Bicara Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Bicara Therapeutics (NASDAQ:BCAX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Scholar Rock is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A

Scholar Rock presently has a consensus target price of $56.00, indicating a potential upside of 1.82%. Bicara Therapeutics has a consensus target price of $30.27, indicating a potential upside of 1.96%. Given Bicara Therapeutics' higher probable upside, analysts plainly believe Bicara Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73

Bicara Therapeutics' return on equity of -35.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Bicara Therapeutics	N/A	-35.89%	-33.78%

In the previous week, Scholar Rock had 2 more articles in the media than Bicara Therapeutics. MarketBeat recorded 4 mentions for Scholar Rock and 2 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.94 beat Scholar Rock's score of 0.81 indicating that Bicara Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.1% of Scholar Rock shares are owned by institutional investors. 13.3% of Scholar Rock shares are owned by insiders. Comparatively, 13.8% of Bicara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Scholar Rock has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, Bicara Therapeutics has a beta of -0.54, indicating that its stock price is 154% less volatile than the broader market.

Summary

Bicara Therapeutics beats Scholar Rock on 8 of the 14 factors compared between the two stocks.

How does Bicara Therapeutics compare to CG Oncology?

Bicara Therapeutics (NASDAQ:BCAX) and CG Oncology (NASDAQ:CGON) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

CG Oncology's return on equity of -23.33% beat Bicara Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bicara Therapeutics	N/A	-35.89%	-33.78%
CG Oncology	N/A	-23.33%	-22.24%

Bicara Therapeutics currently has a consensus price target of $30.27, indicating a potential upside of 1.96%. CG Oncology has a consensus price target of $81.73, indicating a potential upside of 15.03%. Given CG Oncology's higher possible upside, analysts plainly believe CG Oncology is more favorable than Bicara Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bicara Therapeutics	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.73
CG Oncology	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

26.6% of CG Oncology shares are held by institutional investors. 13.8% of Bicara Therapeutics shares are held by insiders. Comparatively, 4.8% of CG Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, CG Oncology had 10 more articles in the media than Bicara Therapeutics. MarketBeat recorded 12 mentions for CG Oncology and 2 mentions for Bicara Therapeutics. Bicara Therapeutics' average media sentiment score of 0.94 beat CG Oncology's score of 0.63 indicating that Bicara Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bicara Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	4 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Bicara Therapeutics has higher earnings, but lower revenue than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bicara Therapeutics	N/A	N/A	-$137.95M	-$2.78	N/A
CG Oncology	$5.07M	1,235.80	-$160.99M	-$2.33	N/A

Bicara Therapeutics has a beta of -0.54, meaning that its stock price is 154% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.31, meaning that its stock price is 69% less volatile than the broader market.

Summary

CG Oncology beats Bicara Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Bicara Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCAX vs. The Competition

Export

Metric	Bicara Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.63B	$6.76B	$12.60B
Dividend Yield	N/A	2.21%	2.66%	6.21%
P/E Ratio	-10.68	21.26	27.33	24.88
Price / Sales	N/A	336.31	561.02	115.95
Price / Cash	N/A	62.10	29.14	36.96
Price / Book	4.05	8.74	11.00	6.56
Net Income	-$137.95M	$23.81M	$3.57B	$336.70M
7 Day Performance	18.76%	3.64%	2.57%	3.31%
1 Month Performance	36.51%	1.64%	0.90%	1.68%
1 Year Performance	219.59%	69.47%	36.85%	31.96%

Bicara Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCAX Bicara Therapeutics	1.1099 of 5 stars	$29.69 +1.2%	$30.27 +2.0%	+236.9%	$1.95B	N/A	N/A	32	News Coverage High Trading Volume
CNTA Centessa Pharmaceuticals	1.8892 of 5 stars	$40.50 +0.8%	$41.33 +2.1%	N/A	$6.21B	N/A	N/A	200	Short Interest Decrease High Trading Volume
COGT Cogent Biosciences	1.5303 of 5 stars	$36.31 +1.3%	$43.73 +20.4%	+445.6%	$6.12B	N/A	N/A	80
BLTE Belite Bio	3.7036 of 5 stars	$145.09 -1.3%	$203.00 +39.9%	+161.9%	$5.90B	N/A	N/A	10	Positive News
SRRK Scholar Rock	1.4853 of 5 stars	$51.27 +4.2%	$56.00 +9.2%	+53.5%	$5.89B	N/A	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCAX) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bicara Therapeutics (BCAX) Competitors

BCAX vs. CNTA, COGT, BLTE, SRRK, and CGON

How does Bicara Therapeutics compare to Centessa Pharmaceuticals?

Summary

How does Bicara Therapeutics compare to Cogent Biosciences?

Summary

How does Bicara Therapeutics compare to Belite Bio?

Summary

How does Bicara Therapeutics compare to Scholar Rock?

Summary

How does Bicara Therapeutics compare to CG Oncology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bicara Therapeutics (BCAX) Competitors

BCAX vs. CNTA, COGT, BLTE, SRRK, and CGON

How does Bicara Therapeutics compare to Centessa Pharmaceuticals?

Is BCAX or CNTA more profitable?

Which has preferable valuation and earnings, BCAX or CNTA?

Which has more risk & volatility, BCAX or CNTA?

Do analysts prefer BCAX or CNTA?

Does the media favor BCAX or CNTA?

Do insiders and institutionals believe in BCAX or CNTA?

Summary

How does Bicara Therapeutics compare to Cogent Biosciences?

Is COGT or BCAX more profitable?

Do analysts prefer COGT or BCAX?

Does the media favor COGT or BCAX?

Which has more risk and volatility, COGT or BCAX?

Which has stronger valuation & earnings, COGT or BCAX?

Summary

How does Bicara Therapeutics compare to Belite Bio?

Do analysts prefer BLTE or BCAX?

Does the media refer more to BLTE or BCAX?

Do insiders & institutionals believe in BLTE or BCAX?

Which has more volatility & risk, BLTE or BCAX?

Is BLTE or BCAX more profitable?

Which has stronger earnings & valuation, BLTE or BCAX?

Summary

How does Bicara Therapeutics compare to Scholar Rock?

Which has higher earnings and valuation, SRRK or BCAX?

Do analysts recommend SRRK or BCAX?

Is SRRK or BCAX more profitable?

Does the media refer more to SRRK or BCAX?

Do insiders & institutionals have more ownership in SRRK or BCAX?

Which has more volatility and risk, SRRK or BCAX?

Summary

How does Bicara Therapeutics compare to CG Oncology?

Is BCAX or CGON more profitable?

Do analysts prefer BCAX or CGON?

Do insiders & institutionals believe in BCAX or CGON?

Does the media favor BCAX or CGON?

Which has higher earnings & valuation, BCAX or CGON?

Which has more risk and volatility, BCAX or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCAX vs. The Competition

Bicara Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools